Last reviewed · How we verify
oral Propranolol
Propranolol is a non-selective beta-adrenergic receptor antagonist that blocks the effects of epinephrine and norepinephrine on the heart and blood vessels.
Propranolol is a non-selective beta-adrenergic receptor antagonist that blocks the effects of epinephrine and norepinephrine on the heart and blood vessels. Used for Hypertension, Angina pectoris, Cardiac arrhythmias (including atrial fibrillation and supraventricular tachycardia).
At a glance
| Generic name | oral Propranolol |
|---|---|
| Also known as | Inderal (long-acting), Inderal, Innopran, beta blocker |
| Sponsor | Ahmed talaat ahmed aly |
| Drug class | Non-selective beta-adrenergic antagonist (beta-blocker) |
| Target | Beta-1 and beta-2 adrenergic receptors |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Propranolol competitively inhibits beta-1 and beta-2 adrenergic receptors throughout the body. This reduces heart rate, cardiac contractility, and blood pressure, and also decreases renin release from the kidneys. These effects make it useful for managing hypertension, angina, arrhythmias, and other cardiovascular conditions.
Approved indications
- Hypertension
- Angina pectoris
- Cardiac arrhythmias (including atrial fibrillation and supraventricular tachycardia)
- Myocardial infarction (secondary prevention)
- Essential tremor
- Migraine prophylaxis
- Hyperthyroidism (symptomatic management)
Common side effects
- Fatigue
- Dizziness
- Bradycardia
- Hypotension
- Nausea
- Bronchospasm (in susceptible patients)
- Sexual dysfunction
- Insomnia
Key clinical trials
- Efficacy and Safety of Different Initial Doses of Oral Propranolol in the Treatment of Ulcerated Infantile Hemangioma (PHASE2, PHASE3)
- Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study (PHASE4)
- Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib (PHASE2)
- Propranolol for Early Secondary Prevention of Post-Traumatic Stress Disorder in Women Victims of Sexual Violence (PHASE2)
- A Study of Propranolol to Treat Kaposi Sarcoma (PHASE2)
- Carvedilol vs. Propranolol for Preventing Rebleeding After Endoscopic Treatment of Cirrhotic Varices (PHASE4)
- Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC (PHASE1)
- Modafinil and Cognitive Function in POTS (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- oral Propranolol CI brief — competitive landscape report
- oral Propranolol updates RSS · CI watch RSS
- Ahmed talaat ahmed aly portfolio CI